Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

• DOI: 10.1186/s13058-018-0983-1
• Publication Date: 2018-06-04T08:11:39Z
• Authors: Ricardo Ribas; Sunil Pancholi; Aradhana Rani; Eugene Schuster; Stephanie K. Guest; Joanna Nikitorowi...; Nikiana Simigdala; Allan Thornhill; Francesca Avogadr...; Richard E. Cutler; Alshad S. Lalani; Mitch Dowsett; Stephen R. Johnston; Lesley-Ann Martin
• Keywords: Neoplasms, Hormone-Dependent; Oestrogen receptor; Receptor, ErbB-3; Receptor, ErbB-2; Neratinib; 610; Breast Neoplasms; Mechanistic Target of Rapamycin Complex 1; 03 medical and health sciences; Breast cancer; 0302 clinical medicine; Neoplasms; 616; erbB-3; Humans; Everolimus; Hormone-Dependent; Fulvestrant; RC254-282; erbB-2; Cell Proliferation; 2. Zero hunger; Neoplastic; Epidermal Growth Factor; Estradiol; Aromatase Inhibitors; Estrogen Receptor alpha; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Estrogens; Everomilus; 3. Good health; Gene Expression Regulation, Neoplastic; Tamoxifen; Gene Expression Regulation; MCF-7 Cells; Quinolines; Female; Receptor; Endocrine resistance; Research Article; Signal Transduction

Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER+) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing the need for steroid hormones. Previously, we reported the anti-proliferative effect of everolimus (RAD001-mTORC1 inhibitor) with endocrine therapy in resistance models; however, potential routes of escape from treatment via ERBB2/3 signalling were observed. We hypothesised that combined targeting of three cellular nodes (ER, ERBB, and mTORC1) may provide enhanced long-term clinical utility.A panel of ER+ BC cell lines adapted to long-term oestrogen deprivation (LTED) and expressing ESR1 wt or ESR1 Y537S , modelling acquired resistance to an aromatase-inhibitor (AI), were treated in vitro with a combination of RAD001 and neratinib (pan-ERBB inhibitor) in the presence or absence of oestradiol (E2), tamoxifen (4-OHT), or fulvestrant (ICI182780). End points included proliferation, cell signalling, cell cycle, and effect on ER-mediated transactivation. An in-vivo model of AI resistance was treated with monotherapies and combinations to assess the efficacy in delaying tumour progression. RNA-seq analysis was performed to identify changes in global gene expression as a result of the indicated therapies.Here, we show RAD001 and neratinib (pan-ERBB inhibitor) caused a concentration-dependent decrease in proliferation, irrespective of the ESR1 mutation status. The combination of either agent with endocrine therapy further reduced proliferation but the maximum effect was observed with a triple combination of RAD001, neratinib, and endocrine therapy. In the absence of oestrogen, RAD001 caused a reduction in ER-mediated transcription in the majority of the cell lines, which associated with a decrease in recruitment of ER to an oestrogen-response element on the TFF1 promoter. Contrastingly, neratinib increased both ER-mediated transactivation and ER recruitment, an effect reduced by the addition of RAD001. In-vivo analysis of an LTED model showed the triple combination of RAD001, neratinib, and fulvestrant was most effective at reducing tumour volume. Gene set enrichment analysis revealed that the addition of neratinib negated the epidermal growth factor (EGF)/EGF receptor feedback loops associated with RAD001.Our data support the combination of therapies targeting ERBB2/3 and mTORC1 signalling, together with fulvestrant, in patients who relapse on endocrine therapy and retain a functional ER.